A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01262534 |
Recruitment Status
:
Completed
First Posted
: December 17, 2010
Last Update Posted
: May 6, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Psoriasis | Other: Clinical profile of patients Other: Patient Preferences about treatment Other: Quality of Life |
Study Type : | Observational |
Actual Enrollment : | 1042 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Official Title: | Observational Epidemiological Registry to Assess the Clinical Profile in Patients With Moderate to Severe Psoriasis in Spain |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | June 2011 |
Actual Study Completion Date : | June 2011 |

Group/Cohort | Intervention/treatment |
---|---|
1
Clinical profile of patients Comorbidities and associated type of treatments will be collected.
|
Other: Clinical profile of patients
Comorbidities and associated type of treatments will be collected.
|
2
Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
|
Other: Quality of Life
The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
|
3
Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
|
Other: Patient Preferences about treatment
Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patient over 18 years of age
- Diagnosed with psoriasis at least 6 months before the visit
- Diagnosed with moderate to severe psoriasis
- Who have been treated or not for moderate to severe psoriasis
- For whom the medical history dating back at least 6 months can be accessed
- the patient's legal representative has signed informed consent, stating that the patient understands the study purpose and requirements and grants the patient consent to participate in the study
Exclusion Criteria:
- Patient diagnosed with mild psoriasis according to the dermatologist or with a skin disease other than psoriasis
- With any type of difficulty understanding the questions in the DLQI, SF-36 and PBI questionnaires
- Who and/or whose legal representative refuses to grant written, informed consent to participate in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01262534
Study Director: | Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial | Janssen-Cilag, S.A. |
Responsible Party: | Janssen-Cilag, S.A. |
ClinicalTrials.gov Identifier: | NCT01262534 History of Changes |
Other Study ID Numbers: |
CR017545 CNTO1275PSO4013 ( Other Identifier: Janssen-Cilag S.A., Spain ) |
First Posted: | December 17, 2010 Key Record Dates |
Last Update Posted: | May 6, 2013 |
Last Verified: | May 2013 |
Keywords provided by Janssen-Cilag, S.A.:
Psoriasis comorbidities, associated treatment, quality of life |
Additional relevant MeSH terms:
Psoriasis Skin Diseases, Papulosquamous Skin Diseases |